EvaluatePharma’s new service focuses on medical device and diagnostic sector

EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today announced the launch of EvaluateMedTech™, a new intelligence service focused on the medical device and diagnostic sector. Powered by EvaluatePharma's proven platform and high quality data, EvaluateMedTech™ allows companies, investment banks, management consultancies and service providers to easily track and benchmark the sector in a one-stop, up-to-date online platform.

"For more than a decade, our team has provided the global pharmaceutical market with independent, clear and concise intelligence unrivaled in the industry. We are pleased to now extend our analysis to the medical device and diagnostic industry," said Dr. Jonathan de Pass, CEO of EvaluatePharma Ltd.

EvaluateMedTech™ is designed to help those involved in the medtech industry to compete effectively in the global market and increase shareholder value and ROI. Its unique insights, derived from public company information, equity analyst reports, regulatory approvals, clinical trials, press releases and venture financing data, among other sources, provide an easy way to derive business answers. It provides:

• The first consensus view of the medtech industry including company segment and product consensus sales forecasts to 2018.
• The first database to model in detail sales from the devices that comprise a company's reported segments and correlate those to rich data sources and news.
• Six integrated Devices@FDA databases for access to filings and approvals, along with EU CE Mark news and Japan PDMA approvals.
• A proprietary medtech portfolio database to track R&D and marketed devices for a comprehensive device lifecycle picture.

As part of the new service, EvaluatePharma will release its first annual EvaluateMedTech World Preview report at the 2012 AdvaMed conference in Boston on October 1, 2012.  The complimentary report provides top insights into the medtech sector, including the expected performance of the industry through 2018.